New drug combo aims to fight Hard-to-Treat colorectal cancer
Disease control
Recruiting now
This phase 2 trial tests whether combining two drugs—fruquintinib and TAS-102—works better than fruquintinib alone for people with advanced colorectal cancer that hasn't responded to prior treatments. About 120 adults will be randomly assigned to one of the two groups. The main g…
Phase: PHASE2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC